DALIRESP
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $446.77 | 11 | 11 |
| 2022 | $225.85 | 9 | 9 |
| 2020 | $2,386 | 137 | 110 |
| 2019 | $188,715 | 877 | 575 |
| 2018 | $172,124 | 239 | 181 |
| 2017 | $179,371 | 41 | 24 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $380,846 | 21 | 70.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $118,175 | 72 | 21.8% |
| Food and Beverage | $27,354 | 1,161 | 5.0% |
| Travel and Lodging | $10,821 | 49 | 2.0% |
| Consulting Fee | $5,982 | 4 | 1.1% |
| Education | $90.00 | 7 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 G ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID LABAICS | Allergan Inc. | $198,097 | 0 |
| Effects of Roflumalist in Hospitalized COPD on Mortality and Re Hospitalization | AstraZeneca Pharmaceuticals LP | $109,206 | 0 |
| SPIROMICS Exacerbation Sub Study | AstraZeneca Pharmaceuticals LP | $40,000 | 0 |
| Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients | AstraZeneca Pharmaceuticals LP | $28,869 | 0 |
| Adequacy of dalbavancin in cement spacer | Allergan Inc. | $4,573 | 0 |
| DISEASE-MODIFYING EFFECTS OF ROFLUMILAST IN MOUSE MODELS OF COPD | Allergan Inc. | $101.60 | 0 |
Top Doctors Receiving Payments for DALIRESP
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Bethesda, MD | $380,846 | 21 |
| , MD | Internal Medicine | Lexington, KY | $19,629 | 17 |
| , MD | Pulmonary Disease | Denver, CO | $9,957 | 8 |
| , MD | Critical Care Medicine | Rochester, NY | $8,365 | 13 |
| , DO | Pulmonary Disease | Mesa, AZ | $7,419 | 12 |
| , D.O | Critical Care Medicine | Altoona, PA | $5,546 | 9 |
| , M.D | Pulmonary Disease | San Antonio, TX | $5,521 | 6 |
| , MD | Pulmonary Disease | Columbus, OH | $4,997 | 4 |
| , MD | Internal Medicine | Anderson, SC | $4,996 | 7 |
| , MD | Pulmonary Disease | Chattanooga, TN | $4,569 | 7 |
| , MD | Critical Care Medicine | Plantation, FL | $4,543 | 7 |
| , M.D | Specialist | Panama City, FL | $4,431 | 4 |
| , MD | Pulmonary Disease | Waterbury, CT | $4,240 | 6 |
| , M.D | Internal Medicine | Greensboro, NC | $3,555 | 4 |
| , MD | Critical Care Medicine | Waco, TX | $3,495 | 4 |
| , DO | Allergy & Immunology | Clinton Township, MI | $3,186 | 5 |
| , M.D | Pulmonary Disease | Hopewell, VA | $2,800 | 2 |
| , M.D | Specialist | Tyler, TX | $2,456 | 4 |
| , MD | Pulmonary Disease | Salem, VA | $2,450 | 1 |
| , M.D | Pulmonary Disease | Nashville, TN | $2,434 | 2 |
| , M.D | Critical Care Medicine | Canton, OH | $2,378 | 5 |
| , M.D | Pulmonary Disease | Jackson, MS | $2,348 | 2 |
| , MD | Critical Care Medicine | Salem, UT | $2,150 | 1 |
| Henry Ostman | Pulmonary Disease | Lemoyne, PA | $2,024 | 4 |
| , MD | Critical Care Medicine | Oakland Park, FL | $1,937 | 3 |
Manufacturing Companies
- AstraZeneca Pharmaceuticals LP $340,154
- Allergan Inc. $203,053
- ABBVIE INC. $61.78
Product Information
- Type Drug
- Total Payments $543,269
- Total Doctors 843
- Transactions 1,314
About DALIRESP
DALIRESP is a drug associated with $543,269 in payments to 843 healthcare providers, recorded across 1,314 transactions in the CMS Open Payments database. The primary manufacturer is AstraZeneca Pharmaceuticals LP.
Payment data is available from 2017 to 2024. In 2024, $446.77 was paid across 11 transactions to 11 doctors.
The most common payment nature for DALIRESP is "Unspecified" ($380,846, 70.1% of total).
DALIRESP is associated with 6 research studies, including "A 52-WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECT OF ROFLUMILAST 500 G ON EXACERBATION RATE IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD TREATED WITH A FIXED-DOSE COMBINATION OF LONG-ACTING BETA AGONIST AND INHALED CORTICOSTEROID LABAICS" ($198,097).